| 4. |
- Hammarsten, J, et al.
(author)
-
HYPOADIPONECTINEMI – A RISK FACTOR FOR BENIGN PROSTATIC HYPERPLASIA
- 2009
-
In: International Congress on Prediabetes and the Metabolic Syndrome.
-
Conference paper (other academic/artistic)abstract
- HYPOADIPONECTINEMI – A RISK FACTOR FOR BENIGN PROSTATIC HYPERPLASIA Authors: J Hammarsten1, C J Behre2, J-E Damber3, T Knutson3, R Peeker3, D Mellström 4 (1)Skaraborg Hospital, Department of Urology, Skövde, Sweden, (2) Sahlgrenska University Hospital, Institute of Internal Medicine, Göteborg, Sweden, (3) Sahlgrenska University Hospital, Department of Urology, Göteborg, Sweden, (3) Sahlgrenska University Hospital, Center for bone research at the Sahlgrenska Academy, Department of Internal Medicine, Göteborg, Sweden Hypoadiponectinemi has recently been shown to be related to the metabolic syndrome. Our group has over the last 15 years suggested that benign prostatic hyperplasia (BPH) is a component of the metabolic syndrome. In our reports we have found that 19 out of 21 conditions that are associated to the metabolic syndrome also were risk factors for BPH. The aim of the present study was to investigate the correlation between serum adiponectin levels and BPH. Given the strong correlation between BPH and the metabolic syndrome, it could be hypothesized that there is a statistical significant inverse correlation between the prostate gland volume and the circulating adiponectin levels. Material and methods: One thousand representative men, aged 72 – 76 years, living in Göteborg, Sweden involved in the Mr Os study were recruited. The Mr Os study is an international study of male osteoporosis. In 184 men, a subgroup of the total population, the prostate gland volume was determined. Serum adiponectin was determined using human adiponectin ELISA kit. Results: Men, previously diagnosed with prostate cancer or having had a prostate operation, were excluded after which 157 men remained. The mean prostate gland volume was 46 ml (13 – 139 ml). The mean adiponectin level was 11.2+5.7µg/mL(SD). Using univariate analysis, adiponectin correlated inversely with the prostate gland volume (R=-158, P=0.0481). Using multivariate analysis, adjusting for insulin, glucose and trunk fat mass, adiponectin did not come out statistically significantly. In the total material, adiponectin correlated inversely with insulin (R=-0.340, P<0.0001), glucose (R=-0.186, P<0.0001), BMI (R=-0.271, P<0.0001, trunk fat mass (R=-0.315, P<0.0001) and lean body mass (R=-0.185, P<0.0001). Conclusion: Our data show for the first time that hypoadiponectinemi is a risk factor for BPH. This is in conjunction with our suggestion that BPH is a component of the metabolic syndrome. Our data also confirm that hypoadiponectinemi is related to the metabolic syndrome.
|
|
